EUCTR2011-002092-42-GB进行中（未招募）不适用
Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 years to 75 years
- •2. Presence of of persistent neuropathic pain for at least 6 months at the time of the Enrollment Visit. Allowed reasons for neuropathic pain are modified radical mastectomy or breast conserving surgery, or cosmetic breast surgery, lateral and postero-lateral thoracotomy, traumatic nerve lesions of upper or lower limb, and post herpetic neuralgia.
- •3. Presence of probable” or definite” neuropathic pain.
- •4. Presence of dynamic mechanical allodynia on the affected side, or alternatively, the mechanical pain sensitivity for any of the pinprick stimuli is higher on the affected compared to the contralateral side.
- •5. At either Visit 5 or Visit 6: Presence of an average evoked pain intensity score of >20 on the 0 100 point numeric rating scale (NRS) for at least 1 of the 3 clinical sub-tests for dynamic mechanical allodynia (i.e., standardized brush [Somedic, Sweden], cotton wool tip or cotton wisp). The average will be calculated as the arithmetic mean of all measurements per sub test. Alternatively, the arithmetic mean of the 5 test replicates for any of the pinprick stimuli for mechanical pain sensitivity is at least 3 times higher for the affected side compared to the contralateral side.
- •6. Presence of an average ongoing pain intensity score of >4 to <9 on the 0-10 point numerical rating scale (NRS) without the use of rescue medication within the 3 day Baseline pain intensity evaluation Period with at least 7 of 9 assessments being present.
- •7. Dissatisfaction with the current treatment (i.e., lack of efficacy or intolerable side effects) if taking an opioid or non opioid analgesic medication for the painful neuropathy before enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Any kind of hepatic impairment at Visit 1 or at Visit 3.
- •2. Either active hepatitis within the past 3 months or presence of chronic hepatitis irrespective of its activity status.
- •3. Estimated creatinine clearance of less than 60 mL/minute x 1.73 m2 (Modification of Diet in Renal Disease [MDRD]-formula with correction by body surface [Levey et al. 1999]) at either Visit 1 or at Visit 3.
- •4. Clinically relevant cardiac disease (e.g., unstable angina pectoris, angina pectoris Canadian Cardiovascular Society [CCS] Grade III to IV, acute myocardial infarction within the last 3 months, cardiac insufficiency New York Heart Association [NYHA] Class III to IV).
- •5. Electrocardiogram (ECG) with clinically relevant findings at either Visit 1 or at Visit 3, including but not limited to repeated prolongation of QTc > 450 ms (Fredericia correction), or a history of additional risk factors for torsade de pointes (e.g., family history of Long QT Syndrome).
- •6. Clinically relevant pulmonary disease (e.g., Medical Research Council breathlessness scale of 2 or above).
- •7. Specific antitumor therapy within the last 6 months, e.g., adjuvant radiotherapy or chemotherapy, biologics, or angiogenesis inhibitors.
- •8. CYP2D6 poor metabolizer phenotype as predicted by CYP2D6 genotyping.
- •9. Presence of confounding pain conditions (e.g., ulnar nerve entrapment, radial nerve injury associated with major soft-tissue or bone damage, cervico-thoracic radiculopathy, carpal tunnel syndrome, chemotherapy-induced peripheral neuropathy, or complex regional pain syndrome type I or type II).
- •10. Phantom breast or phantom limb pain.
- •11. Presence of exclusively negative symptoms of neuropathic pain (e.g., hypoesthesia or total anesthesia) in the affected area.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the therapeutic effectiveness and safety of 7 days of treatment with a novel analgesic in subjects with peripheral neuropathic paiEUCTR2011-002092-42-HUGrünenthal GmbH90
进行中（未招募）
不适用
Evaluation of the therapeutic effectiveness and safety of 7 days of treatment with a novel analgesic in subjects with peripheral neuropathic paimononeuropathic pain due to post-herpetic neuralgia, post-operative neuropathic pain, or traumatic nerve injuryMedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 100000004852EUCTR2011-002092-42-PLGrünenthal GmbH90
进行中（未招募）
不适用
Evaluation of the therapeutic effectiveness and safety of 7 days of treatment with a novel analgesic in subjects with peripheral neuropathic paimononeuropathic pain due to post-herpetic neuralgia, post-operative neuropathic pain, or traumatic nerve injuryMedDRA version: 14.1Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002092-42-DEGrünenthal GmbH90
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
已完成
不适用
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd